Adamant Health redefines Parkinson’s disease analysis

Over 15 years of university research on Parkinson’s and other movement disorders has now empowered the next generation precision in the measurement and analysis of the diseases. Adamant Health transforms world-class academic research into real-life practical benefits for the Parkinson’s disease patients and neurologists.

Currently there are 10 million patients with Parkinson’s disease, and during the next 30 years this number will be more than doubled [1,2]. In the future, over 25 million people are affected by the disease, and it’s only one of the movement disorders [2].

Researcher Saara Rissanen (PhD) has done research on Parkinson’s disease for over 15 years at the University of Eastern Finland in collaboration with the Kuopio and Helsinki University Hospitals, and with international research organizations including Peking University First Hospital and Harvard Medical School. So far, over 20 international scientific articles and research papers have been published, and over 200 patients have been measured in four different countries. This long-term research has now led to the founding of a medical technology company Adamant Health.

“Our innovation in the analysis of neuromuscular function and movement is based on measurement data gathered in international patient studies, and on deep understanding of mathematical algorithms. With our solution, we can measure multiple neuromuscular disturbances, and through that, analyse motor symptoms and their fluctuation in time. Founding Adamant Health allows us to distribute the benefits of the research findings to a broader audience”, says Adamant Health’s CTO, Chief Scientist and founder Saara Rissanen.

Modern medicine has no means to prevent or cure Parkinson’s disease [3]. That’s why it is extremely important to focus on relieving patients’ symptoms and supporting the neurologists in coming up with the best treatment plan. Adamant Health brings objective and precise patient and reference data to the treatment process. The data not only supports neurologists in planning the treatment and medication but also frees the patient and caregivers from the burden of keeping a detailed symptom diary. Moreover, Adamant Health provides better means to the pharmaceutical industry to develop more efficient and safe drugs. That’s possible with the comparable patient measurement data registered long-term with high level of precision. Adamant Health is able to reliably and objectively measure the patient during the everyday life.

“Adamant Health’s technology is one of the kind globally. This has led to a huge global interest towards our measuring and analysis services especially from the drug industry and academic movement disorder researchers. The technology is planned to be available for clinical use latest during the next summer. This opens unique opportunities to help patients globally and develop into a sustainable business”, says Adamant Health’s CEO and founder, Paulus Carpelan.

Adamant Health has closed its latest investment round to support the development and expansion of its operations. The plan is to begin seizing the benefits of the research on a bigger scale for the research, drug development and treatment of Parkinson’s disease. The lead investor of the round is Voima Ventures known for deep tech, and science and research based investments. Other investors include COR Group specializing in medical technology investments, and angel investors.

“With over 20 years of experience in the global medical technology sector makes us sure about the huge global potential Adamant Health’s technology has in the neurological care space. Our goal is to act as a long term strategic partner to Adamant Health, and work together as an active board member and one of the owners”, says co-founder and board member of COR Group, Olli Karhi.

“For investors today there are an enormous number of good investment opportunities. However, there are so few ones with potential to become the gold reference of their entire industry. Adamant has that potential. Hence, we are super happy to be with this great venture and team“, says Venture Partner of Voima Ventures and angel investor, Harry Santamäki.

Source: Voima Ventures